Seladelpar L-Lysine Dihydrate is a therapeutic agent used as an oral treatment for primary biliary cholangitis, a rare chronic liver disease, by acting as a selective peroxisome proliferator-activated… Read more



Seladelpar L-Lysine Dihydrate is a therapeutic agent used as an oral treatment for primary biliary cholangitis, a rare chronic liver disease, by acting as a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. This category provides essential reference standards for the parent drug, including its synthesis-related impurities, potential degradation products, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these high-quality reference materials for impurity profiling, method development, and rigorous quality control protocols during analytical testing. By offering these precise chemical standards, the collection supports the validation of stability-indicating methods and ensures compliance with regulatory requirements throughout the drug development and manufacturing lifecycle. These compounds are critical for researchers and quality control scientists who require accurate analytical benchmarks for characterizing the safety and integrity of this specific liver-targeting medication.